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Summary.-In a clinical investigation ofobserved postoperative survival,563 patients
have been registered for primary surgical treatment of colorectal cancer since 1974.
The potential prognostic factors examined within the first days of hospitalization for
primary resection included age of the patients, operability, location of the tumour,
tumour extension and the preoperative serum CEA level. Statistical treatment of the
data revealed that each of the clinical parameters except tumour location covers
ranges associated with highly significant differences in survival of the patients. The
preoperative serum CEA level gave prognostic information in addition to operability
or tumour extension. The prognostic significance of the preoperative CEA level was
still evident when selected subgroups of patients with distinct resectability and
tumour extension were examined. The results indicate that the preoperative serum
CEA level is an independent prognostic parameter.
THE ASSAY for serum carcinoembryonic
antigen (CEA) performed in intervals of
2-3 months is the most valuable adjunct
to clinical examination in postoperative
monitoring of patients with resected
colorectal cancer. Consecutively rising
CEA levels usually predict disease recur-
rence several months before clinical de-
tection. The rate ofrise of the serum CEA
level represents a basis for discriminating
between localized recurrence and meta-
static spread (Staab et al., 1978; Wood
et al., 1980; Steele et al., 1980). However,
there are relatively few studies on the
prognostic value of preoperative serunm
CEA levels. Wanebo et al. (1978), Evans
et al. (1978) and Goslin et al. (1-980)
published a statistical treatment of the
correlation of preoperative CEA levels
and disease recurrence. In these reports
positive correlation was highly significant.
In another report preoperative plasma
CEA levels of 42 patients correlated
inversely with survival at a statistically
significant level (Kohler et al., 1980).
Our present study, part of a long-term
follow-up of patients with colorectal car-
cinoma started by us in 1974, was set up to
characterize prognostic parameters which
could be established within a few days,
still during hospitalization of patients for
primary treatment. The most important
question in this investigation was whether
a molecular marker (i.e. the serum CEA
level) determined shortly before surgical
treatment, does represent a gain in prog-
nostic information in addition to the clini-
cal parameters of tumour extension, site
of the tumour and resectability. The data
obtained from 563 patients were con-
sidered sufficient for a preliminary statis-
tical analysis. The statistical treatment of
the data was based on the observed sur-
vival, and included subgroups of the main
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prognostic parameters (a) tumour exten-
sion, (b) resectability, (c) preoperative
CEA level, (d) age, (e) tumour location,
as well as subgroups with selected com-
binations of 3 of those parameters. The
results indicate a significant gain in prog-
nostic information when the preoperative
CEA level was included as a direct prog-
nostic parameter.
PATIENTS AND METHODS
Patients.-563 patients (male:female=
1:16) were registered for primary resection of
carcinomas of the sigmoid colon (n=222),
ascending,transverseanddescendingcolonand
caecum (n= 128) or rectum (n=213) in the
ChirurgischeKlinik,Stuttgart-Bad-Cannstatt,
since 1974. In all cases the resected tumours
and biopsies were characterized histologically.
Blood samples were taken the first or second
day of hospitalization prior to surgery. For
the characterization of the extent of the
tumours we used the TNM classification of
the International Union Against Cancer
(UICC) (1978) and in colon carcinomas oper-
ated before 1978, an institutional TNM-
classification. The criteria of this classifica-
tion were essentially the same as had been
described by Holyoke et al. (1975) differing
from that of the UICC only in minor points.
Resectability of tumours was classified by
the surgeon according to the categories
"radical resection", ''palliative resection"
and "nonresectable" as judged from the
operative findings and the pathologist's
report. "Nonresectable" means that surgery
was limited to explorative laparotomy and
biopsies only.
All patients were registered for a post-
operative follow-up, which included routine
serum CEA determinations and examinations
every 2-3 months. A computerized recall
program was developed to keep contact with
the patients. In cases of death not registered
in the clinic, confirmation was obtained from
the family doctor, the relatives of the patient
or the local community administration.
CEA assay.-Serum CEA concentrations
were assayed with the CEA-Roche-RIA test
kit (lloffmann-La Roche, Basel, Switzerland)
using the Hansen Z-gel method (Hansen et at.,
1971) according to the instructions given by
Roche Diagnostics, Basel. Possible variations
in the reagents of the commercial CEA-RIA
test kit were controlled on the basis of our
own internal CEA standards throughout the
years. The inter-assay standard deviation
for the CEA determination at concentrations
of 5-7 ng CEA/ml serum was +0-72 and at
concentrations of 10-5 ng CEA/ml, + 0-83.
Statistical analysis. Survival curves were
computed by the life-table method recom-
mended by Peto et al. (1976, 1977) and the
American Joint Committee for Cancer Staging
(1977). To determine the statistical signifi-
cance of differences between the estimated
proportions ofobserved survival in 2 different
groups of patients the logrank test (Peto &
Peto, 1972) was used. Deaths registered dur-
ing the first 30 days after surgery were not
considered tumour dependent and were
excluded from survival curves and signifi-
cance calculations.
RESULTS
Observed survival after primary surgery
of 563 patients with colorectal carcinomas
computed for different location of the
tumours (viz. rectum (re), sigmoid colon
(sc), ascending + transverse + descending
colon and caecum (cc) showed no statis-
tically significant differences in our group
of patients. The logrank test yielded
P=0 15 for cc vs sc, P=0024 for sc vs rc
and P= 0 62 for rc vs cc. Age distribution
was comparable in all 3 groups. Further
computations to characterize the depen-
dence of observed survival on age, oper-
ability, tumour extension and preopera-
tive serum CEA levels were therefore
performed without analysis according to
tumour location.
In a first step, computations ofobserved
survival curves were performed with sub-
groups of patients based on criteria of a
single prognostic variate. In a second step,
combinations of 2 prognostic variables and
in a third step, combinations of 3 prog-
nostic variables were used.
Prognostic criteria based on single
parameters
In the first set of subgroups, the sig-
nificance of differences in survival curves
based on all registered patients (n=563)
was examined for various ranges of age,
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FIG. 1.-Survival curves for subgroups of patients (a) within different age classes, (b) with different
ranges of preoperative serum CEA concentration (,ug/l), (c) with different stages of operability
(R, radical resection; P, palliative resection; NB,, nonresectable) and (d) different stages of tumour
extension (TNM classification). The dotted curve is the survival curve for all patients (no=563).
The total number of patients in each subgroup an(d the statistical significance is listed in Table J.
preoperative CEA. classes of resectability
and tumour extension. The computed sur-
vival curves are given in Fig. 1. Examina-
tion of various age ranges revealed sig-
nificant differences in survival only be-
tween the age groups < 70 and > 70
years (Fig. la); no significant differences
between the survival curves were obtained
for patients younger than 60 years or
between 60 and 70. In Table I the statis-
tical significance (P) is listed together with
the registered number of patients in each
subgroup (no) and the number of cases of
postoperative death occurring within 30
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TABLE I.-Statistical significance of differences between the survival curves of related
subgrotups ofpatients as shown in Fig. 1
p
(for
Graph Subgroups of patients
(a) Age (years) < 70
>70
(b) Preoperative CEA
(Pg/1) 0-2
2-4
4-10
> 10
(c) Operability
Radical resection (R)
Palliative (P)
Nonresectable (NR)
(d) Tumour extension
Tl-2NoMo
T3 NoMo
T4 NoMo
TI-4N1-3Mo
TI-4No-3M1
Age ratio
(<70/>70) no
0.99 280
283
1*02 164
0-89 154
1-06 131
0-95 114
1-06 352
1-01 147
0 54 64
1-12
1 03
0-83
1-18
0-68
66
132
99
153
74
comparison
between
survival
np curves)
25 0-001 24
4 04
6 0.03
8 < 0-001 11
16 <0-001 16 0001 9
0 04
2 00001
10 0-008
6 <0.001
t.= total number of patients registered in each subgroup; np =number of patients dying within 30 days
ofsurgery.
TABLE II.-Statistical significance of differences between the survival curves in related
subgroups ofpatients as shown in Fig. 2
Preoperative CEA
(ttg/l) in patients
according to TNM
Graph classification
(a) T1-2NoMo 0-5
>5
(b) T3NoMo 0-5
>5
(c) T4NoMo 0-5
>5
(d) TI-4N1-3Mo 0-5
>5
* TI-4No-3M1 0-5
>5
nO and np as in Table I.
* Subgroup not shown in Fig. 2.
days of surgery (np) which were excluded
from computations of survival curves and
statistical significance. In addition, for
all subgroups of patients subdivided
according to other potential prognostic
parameters, the age ratio < 70/ > 70 years
was listed to indicate possible age effects.
Computation of the survival curves of
patients with various preoperative serum
CEA levels (Fig. lb) yielded no significant
differences between groupswithCEAinthe
Age ratio
(<70/>70)
1-14
1-00
no
58
8
np
0
0
1-15 97 1
0 75 35 1
057
1-65
1-19
1-18
0-68
0-66
62 4
37 1
92
61
29
45
4
6
3
3
p
0-02
< 0-001
0-02
0-008
0-2
ranges of 0-2 and 2-4 ,ug/l, but significance
was obtained between groups with CEA
ranges of 2-4 and 4-10 ug/l, as well as
between 4-10 and > 10 ,Lg/l (see Table I).
In addition, Fig. lb shows the observed
survival of patients with preoperative
CEA levels > 100 ,ug/l (n0= 16), who were
also included in the group with CEA levels
> 10 ,g/l, and exhibited a distinctly
higher risk.
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Fia. 2. Survival curves for subgroups ofpatients with distinct tumour extension (TNM classification)
according to ranges of preoperative serum CEA level (,tg/l). (a) Patients with Tl-2NoMo tumours-
(b) T3NoMo tumours; (c) T4NoMo tumours and (d) Tl-4NI-3Mo tumours. Each dotted curve is
the survival curve for all patients in a TNM subgroup. The total number of patients in each sub-
group and the statistical significance is listed in Table II.PROGNOSTIC V.ALUE OF SERUM C'EA 657
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FIG. .3. Survival. curves for subgrotups of patients wlho lia(l un(lergone radical (a, b) or palliative (c, d)
resection oftlheir tuimouirs. Subdivisions are based on ranges of preoperative serum CEA concentra-
tion (a, c) oIr TNMA classification (b, d). The (lotted curves represent the survival curves for all
patienits withl radically resected (a, b) or palliatixely resected tumours (c, d). The total ntumber of
patienits in eaclh suLbgrouip an(l the statistical significance is listed in Table III.
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TABLE III.-Statistical significance of differences between the survival
subgroups ofpatients as shown in Fig. 3
curves of related
Age ratio
Graph Subgroups ofpatients (<70/ > 70) nO
Patients with radical resection
(a) Preoperative CEA
(Kg/l) 0-2 1 00 122
2-10 1-07 194
>10 1-25 36
(b) Tumour extension (TNM)
T -2NoMo 1
T3 NoMo 1
T4 NoMo 0
T1-4N -3Mo 1.
Patients with palliative resection
(c) Preoperative CEA
(tg/l) 0-10 1
>10 0O
0-5* 1.
>5* 0
(d) Tumour extension (TNM)
T -4No-3Mo 1
T -4No-3M1 0.l
*13 66
03 130
*91 82
*28 64
*06 103
*91 44
*21 73
*85 74
np
0
2
0
2
1
0
11
5
8
8
*22 100 12
*69 44 4
* Not shown in Fig. 3.
the categories of resectability (viz. R=
radical resection, P =palliative resection
and NR =nonresectable) yielded survival
curves (Fig. lc) showing highly significant
differences (Table I). Patients with non-
resectable tumours had such a poor prog-
nosis that further computations for this
group examining other prognostic para-
meters were omitted. This group also
exhibited a shift in the age distribution,
with more patients > 70 years (Table I).
Computations of the survival curves
based on the criteria of tumour extension
(TNM classification) could be performed
only with 524 patients, since staging of
39 patients was incomplete. The survival
curves of patients subdivided into 5
groups with different degrees of tumour
extension are given in Fig. Id. No sig-
nificant differences were found between
patients with TI-2NoMo tumours and
patients with T3NoMo tumours. However,
the survival curves were significantly
different between patients with T3NoMo
tumours and those with T4NoMo tu-
mours. All cases with lymph-node metas-
tasis showed a significantly lower survival
which was also significantly different
from those with distant metastasis.
Patients with distant metastasis also
showed more
I).
patients > 70 years (Table
Prognostic criteria based on combinations of
two parameters
To test whether the preoperative serum
CEA level is a prognostic factor inde-
pendent of degree of tumour extension,
computations of the survival curves were
performedforgroupsofpatientswithdiffer-
ent tumour extension according to pre-
operative serum CEA levels. The survival
curves ofthese subgroups are given in Fig.
2. Theresults showedsignificantdifferences
between patients with CEA ranges of
0-5 ,ug/l and > 5 ,ug/l in the 4 classes of
tumour extension, TL-2NoMo, T3NoMo,
T4NoMo and T1-4N1-3Mo (Table II).
We also gave the survival curves of
patients with preoperative CEA levels
> 10 jug/l, to illustrate the higher risk of
these patients. In patients with distant
metastasis (TI-4No-3MI) survival was
not significantly dependent on preopera-
tive CEA ranges between 0-5 and > 5 ,ug/l
(P = 0 2; Table II) possibly due to the
greater malignancy of metastasizing tu-
mours.
Survival curves based on the combina-
tion of the two prognostic parameters
p
0-08
<0-001
0 4
0-02
0-08
<0-001
0-018
0-02
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F(,. 4. curve ival es for subgroups of' patienits with ra(lically resectedl Tl-:INo\Io tumnours (a),
T4NoMIo ttumouirs (b), and(1 TI-4N1l-31o tumours (c), an(l xvitlh palliatively reseeted TI-4No-3AMo
ttumouirs (d) aecor(lilng to seruimn CEA level (,ug/I). The dlotte(d curves are the survival curves for) all
patienits registeredl in each of tlhe 4 TNAI subgroups. The number of p)atients in eachl suibgrotup an(d
the statistical signifieance is liste(l in Table IV'.H. J. STAAB ET AL.
tumour extension and preoperative serum
CEA level still included all patients with
nonresectable tumours, who generally
have a poor prognosis. Therefore, compu-
tations were then performed separately
for patients with radically resected tu-
mours and those undergoing palliative
resection. Subgroups were selected based
on different ranges of preoperative CEA.
Furthermore, we examined the prognostic
value of tumour extension combined with
resectability. The resulting survival curves
are shown in Fig. 3. In both the group of
patients with radical resection and those
with palliative resection, subgroups with
distinct ranges of preoperative CEA could
be established showing a significantly
different survival (Table III) based on
preoperative CEA ranges of 0-10 and
> 10 ,ug/l, 0-5 and >5, or 0-2 and 2-10
and > 10 jug/l. Similarly, significantly dif-
ferent survival curves were found in
subgroups of patients with radical or
palliative resection when different stages
of tumour extension were considered
(Table III). Not listed in the table is a
single patient with distant metastasis
(MI) who had undergone radical resection.
These data indicate that all three para-
meters, resectability, tumour extension
and preoperative serum CEA levels, are
of prognostic value for patients, whether
with radically or palliatively resected
colorectal cancer. Survival of patients
with nonresectable tumours revealed no
dependence on preoperative serum CEA
levels.
Prognostic value of combinations of three
parameters
Final confirmation that the preoperative
serum CEA level can be used as indepen-
dent prognostic parameter was obtained
from computations of survival of sub-
groups of patients with distinct resect-
ability and distinct tumour extension.
Patients who had undergone radical
resection were subdivided into subgroups
with the following tumour extensions:
T1-3NoMo, T4NoMo and any tumours
with lymph-node metastasis (TI-4Nl-
3Mo). T1-2NoMo and T3NoMo tumour
stages were combined, since patients with
these stages showed no significantly dif-
ferent survival (see Table III). A single
patient with distant metastasis (MI) but
radical resection was excluded. Patients
who had undergone palliative surgery
were represented by only one subgroup
(TI-4No-3Mo) since survival of patients
with distant metastasis (MI) was not
significantly dependent on preoperative
CEA levels (see Table II). The survival
curves are shown in Fig. 4. The differences
between survival curves based on pre-
operative CEA ranges of 0-5 and >5 ,ug/l
were significant for patients with radical
resection and Tl-3NoMo tumours (Table
IV) but not for patients with radical
resection and lymph-node metastasis (P=
TABLE IV.-Statistical significance of differences between the survival curves of related
subgroups ofpatients as shown in Fig. 4
Pre
CE
su
Graph of
Patients with radical resection
(a) Tl-3NoMo tumours
(b) T4NoMo tumours
(c) TI-4NI-3Mo tumours
)operative
EA (,ug/1)
in
bgroups Age ratio
patients (< 70/> 70) nO
0-5 1-14
>5 0-82
0-5 0-85
>5 1-70
0-5 1-04
> 5 2-16
(d) Patients with palliative resection
and TI-4No-3Mo tumours 0-10
>10
154
42
50
27
45
19
np
1
1
1
0
0
0
1-23 75 7
1-36 25 5
p
< 0-001
0-02
0-1
<0-001
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0 1) possibly due to the few patients in
the subgroups with the CEA range >5
jug/l. Survival curves of patients who
underwent only palliative resection of
tumours with or without lymph-node
metastasis (TI-4No-3Mo) revealed sig-
nificant differences between preoperative
CEA ranges of 0-10 and > 10 ,g/l (Table
IV) but not between 0-5 and >5 kg/l
(P=0-15).
DISCUSSION
The generally accepted prognostic cri-
teria for tumour surgery are resectability,
site of the tumour, tumour extension,
age and general condition of the patient.
A preliminary statistical analysis to ex-
amine the validity of these prognostic
parameters, including the preoperative
serum CEA level as a molecular marker,
was performed with data collected during
a long-term post-operative follow-up of
563 patients with colorectal cancer since
1974. All these potentially prognostic
criteria were available within a short
period of hospitalization for surgery.
The survival curves for various sub-
groups of patients opened up the possi-
bility of comparing different prognostic
parameters, and improving the prognostic
information by combinations of 2 or more
parameters. Resectability (using the cri-
teria "radical resection", "palliative re-
section" and "nonresectable") was con-
firmed as a highly significant prognostic
parameter. Considering the site of the
tumours in colorectal cancer, it is generally
assumed that prognosis improves with the
site of the tumour, in the order rectum <
sigmoid colon < ascending, transverse, de-
scending colon and caecum. In our 563
patients the tumour sites did not represent
a significant prognostic parameter. How-
ever, tumour extension had reliable prog-
nostic value. Though the stages of local-
ized tumour extension (Tl-3NoMo) had
little prognostic value when compared
witheachother, theyshowed asignificantly
improved survival over T4NoMo tumours.
Prognosis became significantly worse when
patients had already developed lymph-
node metastasis or even distant meta-
stasis. The age of patients at surgery
implied prognostic significance for pa-
tients <70 and > 70 years. This finding
has to take into account that prognostic
criteria, such as nonresectability and
distant metastasis as well as a generally
poorer physical condition, are associated
with age over 70 (see Table I) and could
be responsible for the poorer prognosis.
The more important question to be
answered in this report was whether a
molecular marker (i.e. the preoperative
serum CEA level) has prognostic value as a
single parameter or in combination with
other prognostic parameters. Differences
in preoperative CEA ranges between 0-2
and 2-4 jug/lhadnoprognosticsignificance.
However, differences between survival
curves were significant for patients with
CEA ranges of 2-4, 4-10 and > 10 ,tg/l
independent of other prognostic para-
meters such as resectability and tumour
extension. Survival curves of subgroups
of patients based on combinations of the
preoperative CEA levels with a second
and third prognostic parameter confirmed
that distinct preoperative CEA levels can
be independent prognostic markers. Ex-
ceptions were patients with very poor
prognosis, mostly due to far-advanced
tumour progression, i.e. patients with
distant metastasis or nonresectable tu-
mours, who had a very short survival
time. In this group of patients the bio-
logical situation might be predominantly
influenced by additional physiological
disorders such as cachexia, which appar-
ently do not affect the production and
secretion of CEA by tumour cells.
Why the level of CEA secretion into
the serum by tumour cells before surgery
reflects the further development of the
malignant disease, even after radical
resection of the tumour, is little under-
stood. A possible explanation might be
the influence of circulating tumour anti-
gens on immune surveillance as-potential
inducers of suppressor cells. Suppressor
T cells responsive to tumour antigens
prevent both the generation (Greene
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et al., 1977a, b) and expression (Asherson
& Zembala, 1976) of T effector cells.
These suppressor T cells persist after
surgical removal of the tumour (Fujimoto
et al., 1976) whereas the direct blocking
effect of tumour antigens and its irnmune
complexes against T effector cells observed
with tumour-bearer sera disappears within
a few days after tumour removal (Hell-
str6m et al., 1970). A second explanation
may be a direct correlation of the pre-
operative serum CEA level with clinically
undetectable micrometastasis responsible
for the further development of the malig-
nant disease.
The gain in prognostic information
represented by distinct ranges of the pre-
operative serum CEA should facilitate
the management of patients for adjuvant
postoperative treatment such as chemo-
therapy or immunotherapy.
It can be expected that early adoption
ofpostoperative treatment might improve
the prognosis ofpatients. A generalization
from our results has to be based on our
methods. If other CEA test svstems were
used, different critical ranges of the pre-
operative CEA levels would be expected.
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